{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:17:00Z","timestamp":1790864220123,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2003,3]]},"DOI":"10.1038\/nrd1039","type":"journal-article","created":{"date-parts":[[2003,2,28]],"date-time":"2003-02-28T20:17:15Z","timestamp":1046463435000},"page":"177-178","source":"Crossref","is-referenced-by-count":24,"title":["Eplerenone"],"prefix":"10.1038","volume":"2","author":[{"given":"Ruth","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Quirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrd1039_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJM199904223401601","volume":"340","author":"A Mosterd","year":"1999","unstructured":"Mosterd, A. et al. Trends in the prevalence of hypertension, antihypertension therapy, and left ventricular hypertrophy from 1950 to 1999. N. Engl. J. Med. 340, 1221\u20131227 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd1039_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrd873","volume":"1","author":"MA Zaman","year":"2002","unstructured":"Zaman, M. A., Oparil, S. & Calhoun, D. A. Drugs targeting the renin\u2013angiotensin\u2013aldosterone system. Nature Rev. Drug Discov. 1, 621\u2013636 (2002).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd1039_CR3","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","volume":"100","author":"R McKelvie","year":"1999","unstructured":"McKelvie, R. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: The RESOLVD Pilot Study Investigators. Circulation 100, 1056\u20131064 (1999).","journal-title":"Circulation"},{"key":"BFnrd1039_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1749-6632.2002.tb04415.x","volume":"970","author":"R Rocha","year":"2002","unstructured":"Rocha, R. & Funder, J. W. The pathophysiology of aldosterone in the cardiovascular system. Ann. NY Acad. Sci. 970, 89\u2013100 (2002).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrd1039_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S1471-4892(01)00022-4","volume":"1","author":"EG McMahon","year":"2001","unstructured":"McMahon, E. G. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr. Opin. Pharmacol. 1, 190\u2013196 (2001).","journal-title":"Curr. Opin. Pharmacol."},{"key":"BFnrd1039_CR6","first-page":"568","volume":"8","author":"AN Brest","year":"1986","unstructured":"Brest, A. N. Spironolactone in the treatment of hypertension: a review. Clin.Ther. 8, 568\u2013585 (1986).","journal-title":"Clin.Ther."},{"key":"BFnrd1039_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709\u2013717 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd1039_CR8","first-page":"650","volume":"240","author":"M de Gasparo","year":"1987","unstructured":"de Gasparo, M. et al. Three new spironolactone deriatives: characterization in vivo and in vitro. J. Pharmacol. Exp. Ther. 240, 650\u2013656 (1987).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd1039_CR9","unstructured":"FDA Drug Approvals List [online] (cited 27 Jan 2003). \n                    http:\/\/www.fda.gov\/cder\/foi\/label\/2002\/21437lbl.pdf"},{"key":"BFnrd1039_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1161\/01.HYP.37.2.801","volume":"37","author":"T Quaschning","year":"2001","unstructured":"Quaschning, T. et al. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 37, 801\u2013805 (2001).","journal-title":"Hypertension"},{"key":"BFnrd1039_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1524-6175.2002.01510.x","volume":"4","author":"DA Sica","year":"2002","unstructured":"Sica, D. A. Current concepts of pharmacotherapy in hypertension. Eplerenone: a new aldosterone receptor antagonist \u2014 are the FDA restrictions appropriate? J. Clin. Hypertens. 4, 441\u2013445 (2002).","journal-title":"J. Clin. Hypertens."},{"key":"BFnrd1039_CR12","doi-asserted-by":"publisher","first-page":"A24","DOI":"10.1016\/S0895-7061(02)02334-8","volume":"15","author":"M Weinberger","year":"2002","unstructured":"Weinberger, M. et al. Comparison of eplerenone and losartan in patients with low-renin hypertension. Am. J. Hypertens. 15, A24 (2002).","journal-title":"Am. J. Hypertens."},{"key":"BFnrd1039_CR13","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1067\/mhj.2002.129970","volume":"144","author":"M Weber","year":"2002","unstructured":"Weber, M. Clinical implications of aldosterone blockade. Am. Heart J. 144, S12\u2013S18 (2002).","journal-title":"Am. Heart J."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrd1039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd1039","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrd1039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrd1039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:42:35Z","timestamp":1684467755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd1039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["BFnrd1039"],"URL":"https:\/\/doi.org\/10.1038\/nrd1039","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3]]}}}